Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication

Abstract

Hepatitis C virus (HCV) inhibitors include direct-acting antivirals (DAAs) such as NS3 serine protease inhibitors, nucleoside and nonnucleoside polymerase inhibitors, and host-targeting antivirals (HTAs) such as cyclophilin inhibitors that have been developed in recent years. Drug-resistant HCV variants have been reported both in vitro and in the clinical setting for most classes of drugs. We report a comparative study in which the genetic barrier to drug resistance of a representative selection of these inhibitors is evaluated employing a number of resistance selection protocols. The NS3 protease inhibitors VX-950 and BILN 2061, the nucleoside polymerase inhibitor 2-C-methylcytidine, three nonnucleoside polymerase inhibitors (thiophene carboxylic acid, benzimidazole, and benzothiadiazine), and DEB025 were included. For each drug and passage in the selection process, the phenotype and genotype of the drug-resistant replicon were determined. For a number of molecules (BILN 2061 and nonnucleoside inhibitors), drug-resistant variants were readily selected when wild-type replicon-containing cells were directly cultured in the presence of high concentrations of the inhibitor. Resistance to DEB025 could be selected only following a lengthy stepwise selection procedure. For some DAAs, the signature mutations that emerged under inhibitor pressure differed depending on the selection protocol that was employed. Replication fitness of resistant mutants revealed that the C445F mutation in the RNA-dependent RNA polymerase can restore loss of fitness caused by a number of unfit resistance mutations. These data provide important insights into the various pathways leading to drug resistance and allow a direct comparison of the genetic barriers of various HCV drugs.Hepatitis C virus (HCV) is a positive single-stranded RNA virus and the only member of the Hepacivirus genus within the Flaviviridae family. An estimated 170 million people are chronically infected worldwide. Three million to four million people become newly infected each year (57). Chronically infected patients are at increased risk of developing liver cirrhosis and hepatocellular carcinoma. In Western countries, infection with HCV is the most common reason for liver transplantation. The current standard of care for the management of chronic hepatitis C virus infection consists of the combination of pegylated alpha interferon (pegIFN-␣) and ribavirin. This therapy is effective in only 50 to 60% of infected patients and is associated with serious side effects (44). Therefore, more tolerable, highly potent inhibitors of HCV replication are urgently needed and are currently also being developed. Antivirals that specifically target viral proteins are referred to as "direct-acting antivirals" (DAAs) for HCV. A number of NS3/NS4A protease inhibitors are currently in clinical development. The first HCV NS3/4A serine protease inhibitor to enter clinical trials was ciluprevir (BILN 2061) (54), but clinical development was halted because of cardiotoxicity. Other protease inhib...

The Viral Polymerase Inhibitor 2′- C -Methylcytidine Inhibits Norwalk Virus Replication and Protects against Norovirus-Induced Diarrhea and Mortality in a Mouse Model

“…Our attempts to select for resistance to 2CMC in Norwalk virus replicon-carrying cells were unsuccessful (data not shown), which is in line with our failure to select 2CMC-resistant MNV (17). Also against HCV, the barrier to resistance of this nucleoside analogue is high (23).…”

Cross-Genotypic Examination of Hepatitis C Virus Polymerase Inhibitors Reveals a Novel Mechanism of Action for Thumb Binders

“…The loss of activity of benzothiadiazines, such as setrobuvir, against G2a and G3a viruses is consistent with previous reports on chimeric replicons (29,30,32) and recombinant G2a and G3a RdRps (27,28). Resistance to benzothiadiazines in G2a and G3a viruses appears to be due to the glycine residue at position 556 (55,56) of the RdRp, an amino acid substitution which was detected in benzothiadiazine-resistant G1 replicons (60) and in G1 HCV-infected patients after treatment (61). Surprisingly, mutating G556 in the G3a RdRp to a serine, the residue naturally occurring in the G1b enzyme, did not confer susceptibility to benzothiadiazines, at least in recombinant RdRp studies (27).…”

In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance

“…Surprisingly, the C445C/F mutation was also observed following treatment with JT-16, a site I non-nucleoside NS5B inhibitor whose binding pocket does not involve the 445 residue. Clonal sequencing of RNA from the replicon cells revealed that the C445F mutation pre-exists at a frequency of 3.4% (Delang et al, 2011). Moreover, replicons carrying this mutation were markedly more fit when compared to wild-type replicons (Delang et al, 2011).…”